Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy.
Hye-Ran KimJeong-Su ParkJin-Hwa ParkFatima YasminChang-Hyun KimSe Kyu OhIk-Joo ChungChang-Duck JunPublished in: Journal of hematology & oncology (2021)
This work demonstrates that transgelin-2 is an essential protein for both cancer and immunity. Therefore, transgelin-2 can act as a double-edged sword depending on how we apply this protein to cancer therapy. Engineering and clinical application of this protein may unveil a new era in DC-based cancer immunotherapy. Our findings indicate that cell-permeable transgelin-2 have a potential clinical value as a cancer immunotherapy based on DCs.